| HS Code | 958712 |
| Chemical Name | 1,2-Distearoyl-sn-glycero-3-phosphocholine |
| Abbreviation | DSPC |
| Molecular Formula | C44H88NO8P |
| Molecular Weight | 790.2 g/mol |
| Cas Number | 816-94-4 |
| Appearance | White powder |
| Melting Point | ca. 55°C |
| Solubility | Insoluble in water, soluble in chloroform and methanol |
| Purity | ≥98% |
| Storage Temperature | -20°C |
| Synonyms | Distearoylphosphatidylcholine |
| Lipid Class | Phospholipid |
| Origin | Synthetic or natural (derived from animal/plant sources) |
| Stereochemistry | sn-glycero |
| Applications | Liposome formulation, drug delivery, membrane studies |
As an accredited 1,2-Distearoyl-sn-glycero-3-phosphocholine factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | 1,2-Distearoyl-sn-glycero-3-phosphocholine is supplied in a 100 mg amber glass vial with a secure, tamper-evident cap. |
| Shipping | 1,2-Distearoyl-sn-glycero-3-phosphocholine is shipped at ambient temperature, securely packaged in sealed containers to preserve stability and prevent contamination. The chemical is typically shipped in compliance with applicable chemical transport regulations, with appropriate labeling and documentation to ensure safe handling during transit. Avoid exposure to moisture and extreme temperatures. |
| Storage | 1,2-Distearoyl-sn-glycero-3-phosphocholine (DSPC) should be stored at -20°C, protected from light and moisture. It should be kept in a tightly sealed, airtight container under an inert gas, such as nitrogen or argon, to prevent hydrolysis and oxidation. Avoid repeated freeze-thaw cycles to maintain its stability and integrity for long-term use in research applications. |
1,2-Distearoyl-sn-glycero-3-phosphocholine (DSPC) serves as a critical functional phospholipid across advanced production sectors. As a direct manufacturer, we deliver materials conforming to the industry’s highest quality and traceability standards, empowering key innovations in life sciences, pharmaceuticals, and diagnostics. Below, we outline primary industrial use cases where DSPC acts as an indispensable input, detailing compliance obligations, dosage, production methods, and types of final goods.
Pharmaceutical companies depend on DSPC as an essential structural lipid for designing high-stability liposomes in injectable medicines, especially for anticancer agents, mRNA vaccines, and antifungal therapeutics. Its saturated C18:0 acyl chains provide controlled-release profiles and maximize encapsulation efficiency in strict regulatory settings. Manufacturers adjust the DSPC-to-cholesterol molar ratio depending on payload and intended drug release kinetics. Formulation enters at the lipid film hydration or microfluidic mixing stage prior to downstream sizing and purification, governing vesicle rigidity and shelf-life. End formulations include parenteral liposomal doxorubicin, mRNA COVID-19 lipid nanoparticles, and amphotericin B liposomal suspensions for hospital and specialty pharma supply.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
In nutritional manufacturing, DSPC supplies structural stability in advanced liposome-encapsulated nutraceuticals and active dietary ingredients. Its high phase transition temperature extends product shelf life and protects sensitive compounds such as coenzyme Q10, curcumin, and omega-3 triglycerides from oxidation and gastrointestinal degradation. Facilities assess food contact and allergen controls at each blending checkpoint. The DSPC forms multilamellar or unilamellar vesicles during homogenization, often in combination with lecithin and tocopherols. Manufacturers employ incremental DSPC addition based on desired payload capacity and emulsion viscosity, with typical doses reflecting regulatory and claims-driven payload needs. Final supplements range from liquid liposomal vitamins to encapsulated botanical extracts for functional beverage and direct oral delivery.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Producers of in vitro diagnostic (IVD) reagents utilize DSPC for creating stable liposome carriers that enable signal amplification and controlled release in assays such as enzyme immunoassays, lateral flow strips, and biomarker detection kits. Its highly ordered bilayer structure ensures consistent vesicle morphology and long-term batch homogeneity, critical for quantitative accuracy in regulated clinical environments. DSPC is introduced at the liposome formation stage prior to antigen or marker conjugation, with batch compositions verified by DLS and chromatography. Usage ratios vary according to the reporter payload density and buffer compatibility. DSPC-derived vesicles support precise calibration and signal delivery across immunochemistry platforms, enabling manufacturers to meet strict quality control benchmarks.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Hospital compounding facilities and nutrition solution manufacturers incorporate DSPC to stabilize oil-in-water emulsions for parenteral nutrition, especially in products where heat resistance and particle integrity are imperative. Its high gel-to-liquid crystalline phase temperature and saturated lipid chains reduce risk of coalescence during steam sterilization and long-term storage. The material enters at the emulsification stage alongside triglycerides and emulsifying agents. Regulatory authorities closely inspect phospholipid source, traceability, and purity. Appropriate DSPC dose levels depend on droplet size specification, emulsion caloric density, and fat/oil load in the nutritional formula. End dose forms include ready-to-infuse admixtures used in clinical nutrition for intensive care and pediatric hospitals.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Cosmetic manufacturers deploy DSPC in the production of advanced topical formulations where sustained release and skin barrier compatibility are required. It aids in encapsulation and targeted release of active agents like ceramides, antioxidants, and retinoids, improving penetration while protecting sensitive ingredients from external degradation. DSPC integrates into the process at the vesicle formation stage, typically utilizing high-pressure homogenization post-mixing with active extracts and stabilizing agents. Compliance focuses on cosmetic safety and allergenic potential linked to the phospholipid content. Dose levels are matched to active ingredient stability, viscosity, and final skin feel. The resulting products serve as premium serums, anti-aging creams, and dermal repair lotions sold through professional cosmetic channels.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Competitive 1,2-Distearoyl-sn-glycero-3-phosphocholine prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8615365186327 or mail to admin@ascent-chem.com.
We will respond to you as soon as possible.
Tel: +8615365186327
Email: admin@ascent-chem.com
Flexible payment, competitive price, premium service - Inquire now!
Our team has spent years manufacturing high-purity 1,2-Distearoyl-sn-glycero-3-phosphocholine (DSPC). Most folks in our lab know it simply as DSPC or by its CAS number 816-94-4. We know its white, waxy consistency and the unmistakable way it melts—watching technicians test each batch for those signs is just part of our routine. This molecule is a heavyweight in the lipid world, particularly for its roles in drug delivery and research. The model we produce typically shows a purity not less than 99%, which serves researchers and pharmaceutical experts who count on reliability day in, day out.
We won’t get lost in the technical weeds, but the backbone structure—two saturated stearic acid chains at the sn-1 and sn-2 positions, glycerol, and a phosphocholine head group at sn-3—plays a central role in its stability. That’s something we check for in every batch. Simpler chain variations can’t match the same level of robustness under stress. Where other phospholipids may break down, DSPC holds solid at higher temperatures. Researchers running liposome formulations for encapsulation come to us because they want particle stability and long-lasting pharmaceuticals in the vial.
We’ve seen the rise and fall of different phospholipids, and some years back, researchers were more likely to reach for unsaturated options like DOPC in their formulas. But it didn’t take long to see why DSPC stood out in real-world tests. Processes that depend on a tight, sturdy bilayer—like long-acting injectable drugs—just don’t hold up as well with short- or unsaturated chains. DSPC’s high phase transition temperature, usually around 55°C, speaks for itself. It resists phase changes in storage and in the body, so it suits intravenous or inhaled medications where shelf life matters.
During production, controlling for such purity and stability takes vigilance. We draw on years of experience working with hydrogenated natural precursors and synthetic routes to pinch out any impurities, and every batch faces a battery of checks: NMR, HPLC, mass spectrometry. Loss of a single percentage point in purity can mean the difference between a reliable liposome and a broken emulsion in a client’s study.
It’s easy to read marketing sheets about applications, but on our factory floor and labs the story comes alive in formulation rooms. DSPC provides the backbone for many liposomal drugs and vaccine carriers, including some mRNA delivery systems that grabbed headlines. Nanoformulators want carriers that won’t budge under temperature swings or blend into unpredictable mixtures. That’s what drives their choice toward DSPC, not just theory but trial by cold chain and human metabolism.
In our process, every dry, powdery gram of DSPC starts as crude, impure precursor. The purification steps are relentless—column chromatography, multiple solvent evaporations, and constant freeze-drying cycles. These steps ensure clarity and stability, so the molecules won’t add oxidized fats or unknown contaminants to vaccines or therapeutics, especially in products administered to patients.
We partner with formulation teams in pharmaceuticals, from multinationals to rapid-growth biotechs. For many, the sterility of DSPC is non-negotiable. That’s why we carry out microbial and endotoxin controls constantly, batch after batch. There’s rarely room for delays or guesses. Purity and documentation stay at the top of our priority list, observed not only by us but by regulatory inspectors. In liposome research, reproducibility relies on these background details.
There’s a real divide between the experience of using DSPC and other relatives. Take 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC). Compared to DSPC’s saturated chains, DOPC’s double bonds invite oxidation, disorder, and faster degradation. A biologics project that starts out strong falls apart at the stability stage without DSPC. Even our own trial runs with DOPC for long-term liposomal storage quickly forced a return to the more robust, higher-melting DSPC.
Another common option, egg phosphatidylcholine, comes from natural sources. It can show batch-to-batch variation, unpredictable aging, and caveats for those with specific health or dietary restrictions. Synthetics like DSPC let us keep those variables out of the equation. We’ve fielded plenty of calls and emails from teams that tried lecithin blends, only to find issues months into development. By contrast, every batch of DSPC we send comes with specs validated against reference standards. That takes real work and discipline on the plant floor, not just number crunching.
Some clients ask about using hydrogenated soy or egg phospholipids, hoping to save cost. Our own experience shows plenty of lost time and headaches for everyone involved. DSPC’s high melting point and tight chain packing pay dividends in patient results and cold-chain logistics that won’t fail. Those who prioritize outcome over cost tend to switch sooner or later, especially as their volume and regulatory burden grow.
Making DSPC well means confronting challenges every day. Synthetic chemistry doesn’t forgive shortcuts—residual acids, oxidized impurities, or incomplete hydrogenations can spell disaster. Reactions run under nitrogen, monitored for even the smallest off-notes in NMR spectra. Technicians throw out any batch that doesn’t line up with our historical gold standards. Chromatography time, freezer storage, and vacuum drying demand strict adherence to protocol. We walk the line between consistency and innovation, improving yield and purity each year while never losing focus on patient safety or regulatory scrutiny.
Batch traceability has always anchored our process. Each vessel, pipe, and flask in our production system carries documented cleaning and validation records. Raw material identity requires certificates of analysis from trusted suppliers, tested again in our labs for composition and residual solvents. Customers have asked for transparency, not just paper trails. We invite specialist auditors to walk our facility, inspect raw storage, check our batch card system, and review deviation logs. We see risks with each change in supply chain and vet every substitute raw. It costs more but prevents problems before they hit shipping docks or research benches.
A lot gets said about regulatory compliance. Our experience tells us the true test comes when problems arise. Every recall or deviation report we’ve submitted, we treat as a learning opportunity, especially for root cause analysis. The biggest improvements in DSPC production came from listening to researchers, reformulation experts, and even logistics partners. They reported those subtle color changes, clumping in powders, or slow hydration on reconstitution. Each signal gets attention, not excuses.
Recent years introduced new demands for products like DSPC. Vaccine developers, gene therapy labs, and diagnostic researchers pushed supply chains to their limits. Traditional supply was never meant to meet pandemic-scale demand. What we experienced: transport snags, delayed solvents, and a flood of requests for documentation as regulators scrutinized every shipment. As manufacturers, we responded by increasing reactor sizes, retraining staff, and building redundancy into shipping and storage options.
Not every facility pivoted fast enough. Some smaller producers ran into roadblocks with key precursor supplies or couldn’t meet cold-chain requirements. Others struggled to provide detailed certificates users demanded. Our solution rested on scale, but also on decades-old networks of trusted upstream partners and well-honed processes for crisis adaptation. Frequent virtual inspections and secure direct supplier relationships kept raw material variability low, even in global turmoil.
Frequently, teams developing new biologics raise concerns about animal-origin-free production. Our knowledge of both plant-derived and fully synthetic routes matters more now than ever. Researchers count on suppliers who can trace every gram of input and validate non-animal origins with data-backed transparency. Decades in lipid chemistry taught us to anticipate these requests—not just for ethical, but for technical reasons, too. More consistent source materials mean fewer unknowns in downstream analytics, fewer headaches for quality staff, safer products for patients.
Scaling up DSPC production taught us hard lessons. Methods that work at the beaker scale often crumble in the reactor. Solubility becomes a challenge on the kilo scale. Impurities sneak in unless every step, from esterification to phosphocholine addition, stays tightly controlled. Our technical team spent years optimizing every valve, stirrer, and evaporator to guard against trace contaminants—some only visible after weeks in cold storage.
In pilot projects, customer feedback on hydration rates, powder handling, and final encapsulation efficiency gave us a fuller picture than isolated lab testing ever could. Drum and tote packaging required new anti-static liners for powder flow. Even the choice of drum liner plastic affects handling for sensitive labs making injectable drugs. Every packaging and process tweak gets field-tested with clients and logged for future scale-ups.
Process validation is not just a paper exercise for us. We invite client teams to witness cleaning validation runs, line clearances, and end-product sampling. Real transparency, not lip service, ensures we catch missteps before products leave the warehouse. Our own teams sample from each tote and drum for in-house retention, supporting ever-tightening lot-to-lot traceability.
Advances in vaccine delivery, gene editing, and targeted drug delivery depend on making lipids, like DSPC, reliably and at scale. Many breakthrough products in the past few years turned on the tiny difference between pure DSPC and less stable analogs. Our partners push boundaries, sometimes requesting experimental grades for early research or ultraclean material for in vivo studies. Adjusting to these demands meant designing flexible, small-batch syntheses and rigorous quality protocols. We give direct feedback to researchers on feasibility, pilot yields, and risk points. If a process promises better purity or efficiency, we pilot it together in real runs.
Breakthroughs often emerge from working hand-in-hand at the bench with research teams. Fielding urgent questions about solubility, phase transition, or formulation behavior puts our practical experience to work. For electrophysiology, advanced drug encapsulation, or nanoparticle synthesis, unwavering consistency builds trust. We share both our successes and failures, aiming to keep teams from repeating costly mistakes.
For those exploring alternatives or new blends, we remain candid—even if it means saying DSPC’s unique properties cannot be matched by less robust substitutes. Other phospholipids fill other roles, but for long-term, high-stress, and clinical-grade applications, DSPC remains unmatched. Our role is to support researchers in evaluating options pragmatically, not just sell a product but offer substance from years of trial and practice.
Being a producer means constant learning. We see the next wave of client needs already taking shape—higher purity, animal-free status, supply resiliency, and polished documentary support for regulatory filings. Each request, suggestion, and complaint shapes how we tune both our processes and our standards. Sharing our journey with the research and pharmaceutical world keeps us sharp. We invest in new technology not just for efficiency, but to reduce risk and bring down impurity profiles ever closer to theoretical minimums.
Some trends stick—demand for ultra-stable carriers, ongoing regulatory tightening, and specifications that get tighter by the year. Our approach remains rooted in hands-on work. New staff study past batch failures to avoid repeating old issues. Training emphasizes both the science and the nuance—a slightly yellowed powder tells us more than a spreadsheet ever could.
In all the science and paperwork, the goal stays simple: deliver DSPC that enables better medicine, safer delivery, and more predictable research. We see our work as a continuous chain, linking the bench chemistry to the patient and researcher. In a world driven by data and outcomes, quality in every step is not a slogan, but a reflection of daily decisions and years of learning.
We’re not distant from the needs of researchers or developers. Feedback loops between our shop floor, QA team, and client labs direct our improvement efforts. Each person touching DSPC on its journey from raw to finished product becomes part of a narrower pipeline for error and a wider network for innovation. When failures or near-misses arise, we don’t hide. We open the doors, dissect the failure, and put better checks and balances in place.
DSPC is more than a chemical—its journey from bench to batch to bedside embodies trust earned over years of production and collaboration. Our own experience tells us claims are only as strong as the work, openness, and real expertise backing them up. The demands set by regulators and clinicians push us continually, making us sharper, better, and more careful with every year. Those high standards secure a stronger future for both the medicine and the people who depend on it.
